<p>投資低於 10 美元的便宜股票具有很大吸引力。其中一個好處是低股價使您能夠用較少的資金購買更多股票。如果股價大幅上漲，即使是小幅百分比的增長也可以轉化為投資回報的大幅提升。</p>
<p>低價股往往比成熟公司更容易波動。低於 10 美元的便宜股票通常屬於這一類別。這可能存在風險，但一些投資者被潛在的快速利潤吸引，這些利潤來自於正確把握市場時機。</p>
<p>不幸的是，低於 10 美元的便宜股票往往來自於具有有限業績記錄、未經驗證的商業模式或財務困難歷史的公司。這使它們比成熟公司的股票更加風險。然而，本文討論的股票都受益於強勁的營收增長，更重要的是，有盈利。這使它們比絕大多數低價股更加財務穩定。讓我們看看這些公司及其股票。</p>
<h2>DLocal (DLO)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源: Wirestock Creators / Shutterstock.com</p>
<p><strong>DLocal</strong> (納斯達克：<strong>DLO</strong>) 是一家運營支付處理平台的公司，幫助在國際市場，尤其是新興市場運營的企業接受客户支付。隨着金融科技股機會不斷增長和帶來更多消費者上網的機會，這使得它特別具有吸引力。</p>
<p>DLocal 允許商家在他們運營的國家接受各種本地支付方式。這可以包括通過便利店現金支付、銀行轉賬、移動錢包和本地借記卡等支付選項。從高層次上看，DLocal 是國際企業和新興市場客户之間的橋樑。</p>
<p>第一季度支付總額增長了 49%。儘管增長迅速，但較預期較弱的收益使股價下跌。這很好地代表了投資者未來對 DLocal 的預期：強勁的營收增長，但盈利停滯，預計要到 2025 年才會改善。</p>
<p>它仍然為股東提供收益，增長速度超過 30%，並且可以合理地翻倍。這使得 DLO 股票具有潛在突破的價值。</p>
<h2>Fennec Pharmaceuticals (FENC)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源: Billion Photos / Shutterstock</p>
<p><strong>Fennec Pharmaceuticals</strong> (納斯達克：<strong>FENC</strong>) 是一家處於收入階段的生物製藥股票，具有快速增長的潛力。目前股價為 6.30 美元，但兩位分析師認為其價值分別為 15 美元和 17 美元。</p>
<p>該公司稱其主要候選藥物為 PEDMARK。醫生指出，它可預防接受化療的兒童聽力損失。化療可能導致接受治療局部、非轉移性實體腫瘤的小兒患者聽力損失。</p>
<p>這是唯一獲得 FDA 批准用於減少兒童化療患者聽力損失風險的療法。</p>
<p>Fennec Pharmaceuticals 與 Norgine 簽訂了獨家許可協議，以在歐洲、澳大利亞和新西蘭商業化 PEDMARQSI，這是 PEDMARK 在這些地區的同義商標。該公司從該交易中獲得了約 4320 萬美元，並有可能獲得高達約 2.3 億美元的額外商業和監管里程碑。</p>
<p>該公司在最近一個季度末擁有超過 5100 萬美元現金，並總體上產生盈利。</p>
<h2>Direct Digital Holdings (DRCT)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源: weedezign via Shutterstock</p>
<p><strong>Direct Digital Holdings</strong> (納斯達克：<strong>DRCT</strong>) 是另一家低於 10 美元的高風險、高回報股票，具有爆發潛力。該公司提供廣告服務，在 2024 年經歷了起起落落。股價目前為 4 美元左右，在 3 月份飆升至 33 美元以上後有所下跌。</p>
<p>導致急劇下跌的原因很簡單：Direct Digital Holdings 未能達到預期的收入和盈利。預計收入將接近 6600 萬美元，但實際只有 4101 萬美元。這導致每股盈利為-0.08 美元，而預期為 26 美分。</p>
<p>由於這一結果，該公司還大幅調整了其 2024 年的整體展望。該公司現在預計今年銷售額為 1.8 億美元，低於之前的 2.426 億美元。大多數指標表明 DRCT 股票目前定價合理。</p>
<p>今年的收入預計將翻番，盈利增長預計將接近 50%。這次修正為大膽的投資者提供了機會。</p>
<p>_在本文發佈日期，Alex Sirois 在本文中提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈指南。</p>
<p><em>在本文發佈日期，負責編輯在本文中提到的證券中沒有（直接或間接）任何頭寸。</em></p>
<p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的個人股票投資風格側重於長期持有、積累財富的股票選擇。他曾在從電子商務到翻譯再到教育等多個行業工作，並利用他在喬治華盛頓大學獲得的工商管理碩士學位，通過這些技能過濾他的寫作。</p>

DRCT

<p>投資於股價低於 10 美元的便宜股票具有吸引力，因為有可能獲得巨大回報。然而，這些股票通常存在風險，並來自具有有限業績記錄的公司。儘管如此，DLocal、Fennec Pharmaceuticals 和 Direct Digital Holdings 這三支股票顯示出潛力。DLocal 經營支付處理平台，具有強勁的營收增長。Fennec Pharmaceuticals 擁有獲得 FDA 批准的療法，具有快速增長的潛力。Direct Digital Holdings 提供廣告服務，具有高風險、高回報的潛力</p>

<p>Investing in dirt cheap stocks under $10 has a lot of appeal. One of the benefits is that a low share price allows you to buy more shares with a smaller amount of money. If the stock price increases significantly, even a small percentage gain can translate to a large return on your investment.</p>
<div class="lb-trans"><p>投資低於 10 美元的便宜股票具有很大吸引力。其中一個好處是低股價使您能夠用較少的資金購買更多股票。如果股價大幅上漲，即使是小幅百分比的增長也可以轉化為投資回報的大幅提升。</p>
</div><p>Penny stocks tend to be more volatile than established companies. Cheap stocks under $10 often fall into this category. This can be risky, but some investors are drawn to the potential for quick profits that result from timing the market correctly.</p>
<div class="lb-trans"><p>低價股往往比成熟公司更容易波動。低於 10 美元的便宜股票通常屬於這一類別。這可能存在風險，但一些投資者被潛在的快速利潤吸引，這些利潤來自於正確把握市場時機。</p>
</div><p>Unfortunately, cheap stocks under $10 are often from companies with limited track records, unproven business models, or a history of financial difficulties. This makes them much riskier than stocks from established companies. However, the stocks discussed in this article all benefit from strong revenue growth and, more importantly, positive net earnings. That makes them more financially stable than the vast majority of penny stocks. Let’s take a look at those firms and their stocks.</p>
<div class="lb-trans"><p>不幸的是，低於 10 美元的便宜股票往往來自於具有有限業績記錄、未經驗證的商業模式或財務困難歷史的公司。這使它們比成熟公司的股票更加風險。然而，本文討論的股票都受益於強勁的營收增長，更重要的是，有盈利。這使它們比絕大多數低價股更加財務穩定。讓我們看看這些公司及其股票。</p>
</div><h2>DLocal (DLO)</h2>
<div class="lb-trans"><h2>DLocal (DLO)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Wirestock Creators / Shutterstock.com</p>
<div class="lb-trans"><p>來源: Wirestock Creators / Shutterstock.com</p>
</div><p><strong>DLocal</strong> (NASDAQ:<strong>DLO</strong>) operates a payment processing platform that helps businesses operating in international markets, especially emerging markets, accept payments from customers. That makes it especially attractive as the fintech stock opportunity continues to gain momentum and opportunities to bring more consumers online increase.</p>
<div class="lb-trans"><p><strong>DLocal</strong> (納斯達克：<strong>DLO</strong>) 是一家運營支付處理平台的公司，幫助在國際市場，尤其是新興市場運營的企業接受客户支付。隨着金融科技股機會不斷增長和帶來更多消費者上網的機會，這使得它特別具有吸引力。</p>
</div><p>DLocal allows merchants to accept a wide range of local payment methods in the countries they operate in. It can include payment options like cash payments through convenience stores, bank transfers, mobile wallets, and local debit cards, among others. At a high level, DLocal is a bridge between international businesses and customers in emerging markets.</p>
<div class="lb-trans"><p>DLocal 允許商家在他們運營的國家接受各種本地支付方式。這可以包括通過便利店現金支付、銀行轉賬、移動錢包和本地借記卡等支付選項。從高層次上看，DLocal 是國際企業和新興市場客户之間的橋樑。</p>
</div><p>Total payment volume grew by 49% in the first quarter. Despite that rapid growth, weaker-than-anticipated earnings sent shares downward. That’s a fair representation of what investors should expect from DLocal moving forward: strong top-line growth but stagnant earnings that aren’t expected to improve until 2025.</p>
<div class="lb-trans"><p>第一季度支付總額增長了 49%。儘管增長迅速，但較預期較弱的收益使股價下跌。這很好地代表了投資者未來對 DLocal 的預期：強勁的營收增長，但盈利停滯，預計要到 2025 年才會改善。</p>
</div><p>It still provides earnings to shareholders, is growing well above 30%, and can reasonably double in price. That makes DLO stock worthwhile as it harbors breakout potential.</p>
<div class="lb-trans"><p>它仍然為股東提供收益，增長速度超過 30%，並且可以合理地翻倍。這使得 DLO 股票具有潛在突破的價值。</p>
</div><h2>Fennec Pharmaceuticals (FENC)</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals (FENC)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Billion Photos / Shutterstock</p>
<div class="lb-trans"><p>來源: Billion Photos / Shutterstock</p>
</div><p><strong>Fennec Pharmaceuticals</strong> (NASDAQ:<strong>FENC</strong>) is a revenue stage biopharmaceutical stock with the potential to grow rapidly. Shares currently trade for $6.30 but the two analysts covering the equity believe it is worth $15 and $17, respectively.</p>
<div class="lb-trans"><p><strong>Fennec Pharmaceuticals</strong> (納斯達克：<strong>FENC</strong>) 是一家處於收入階段的生物製藥股票，具有快速增長的潛力。目前股價為 6.30 美元，但兩位分析師認為其價值分別為 15 美元和 17 美元。</p>
</div><p>The company calls its leading candidate drug PEDMARK. Doctors indicate it to prevent hearing loss in children undergoing chemotherapy. Chemotherapy can cause hearing loss in pediatric patients undergoing treatment for localized, non-metastatic, solid tumors.</p>
<div class="lb-trans"><p>該公司稱其主要候選藥物為 PEDMARK。醫生指出，它可預防接受化療的兒童聽力損失。化療可能導致接受治療局部、非轉移性實體腫瘤的小兒患者聽力損失。</p>
</div><p>It is the only FDA-approved therapy indicated to reduce the risk of hearing loss associated with chemotherapy in pediatric patients.</p>
<div class="lb-trans"><p>這是唯一獲得 FDA 批准用於減少兒童化療患者聽力損失風險的療法。</p>
</div><p>Fennec Pharmaceuticals executed an exclusive licensing agreement with Norgine to commercialize PEDMARQSI, a synonymous trade name for PEDMARK in Europe, Australia, and New Zealand. The firm received approximately $43.2 million from that deal and has the potential to receive up to approximately $230 million in additional commercial and regulatory milestones.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals 與 Norgine 簽訂了獨家許可協議，以在歐洲、澳大利亞和新西蘭商業化 PEDMARQSI，這是 PEDMARK 在這些地區的同義商標。該公司從該交易中獲得了約 4320 萬美元，並有可能獲得高達約 2.3 億美元的額外商業和監管里程碑。</p>
</div><p>The company had more than $51 million in cash at the end of the most recent quarter and is producing earnings overall.</p>
<div class="lb-trans"><p>該公司在最近一個季度末擁有超過 5100 萬美元現金，並總體上產生盈利。</p>
</div><h2>Direct Digital Holdings (DRCT)</h2>
<div class="lb-trans"><h2>Direct Digital Holdings (DRCT)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: weedezign via Shutterstock</p>
<div class="lb-trans"><p>來源: weedezign via Shutterstock</p>
</div><p><strong>Direct Digital Holdings</strong> (NASDAQ:<strong>DRCT</strong>) is another high-risk, high-reward stock under $10 with the potential to explode. The company provides advertising services and has been up and down in 2024. Shares currently trade for $4 and change after soaring above $33 in March.</p>
<div class="lb-trans"><p><strong>Direct Digital Holdings</strong> (納斯達克：<strong>DRCT</strong>) 是另一家低於 10 美元的高風險、高回報股票，具有爆發潛力。該公司提供廣告服務，在 2024 年經歷了起起落落。股價目前為 4 美元左右，在 3 月份飆升至 33 美元以上後有所下跌。</p>
</div><p>The reason for the sharp decline was straightforward: Direct Digital Holdings missed revenue and earnings expectations by a wide margin. Revenues were anticipated to approach $66 million but came in well short at $41.01 million. That led to a -$0.08 EPS, whereas 26 cents had been expected.</p>
<div class="lb-trans"><p>導致急劇下跌的原因很簡單：Direct Digital Holdings 未能達到預期的收入和盈利。預計收入將接近 6600 萬美元，但實際只有 4101 萬美元。這導致每股盈利為-0.08 美元，而預期為 26 美分。</p>
</div><p>The company also readjusted its overall 2024 outlook sharply as a result. The company now anticipates $180 million in sales this year, down from $242.6 million previously. Most metrics suggest that DRCT shares are currently priced right.</p>
<div class="lb-trans"><p>由於這一結果，該公司還大幅調整了其 2024 年的整體展望。該公司現在預計今年銷售額為 1.8 億美元，低於之前的 2.426 億美元。大多數指標表明 DRCT 股票目前定價合理。</p>
</div><p>Revenues are on track to more than double this year and earnings growth is expected to approach 50%. The correction is an opportunity for brazen investors.</p>
<div class="lb-trans"><p>今年的收入預計將翻番，盈利增長預計將接近 50%。這次修正為大膽的投資者提供了機會。</p>
</div><p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p>_在本文發佈日期，Alex Sirois 在本文中提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈指南。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or</em></p>
<p><em>indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在本文發佈日期，負責編輯在本文中提到的證券中沒有（直接或間接）任何頭寸。</em></p>
</div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p>
<div class="lb-trans"><p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的個人股票投資風格側重於長期持有、積累財富的股票選擇。他曾在從電子商務到翻譯再到教育等多個行業工作，並利用他在喬治華盛頓大學獲得的工商管理碩士學位，通過這些技能過濾他的寫作。</p>
</div>

3 只價格低於 10 美元的超便宜股票可能會大漲！